4.6 Article

Polyomavirus Small t Antigen Interacts with Yes-Associated Protein To Regulate Cell Survival and Differentiation

Journal

JOURNAL OF VIROLOGY
Volume 88, Issue 20, Pages 12055-12064

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01399-14

Keywords

-

Categories

Funding

  1. NIH [CA50661, CA30002, CA34722]

Ask authors/readers for more resources

Murine polyomavirus small t antigen (PyST) regulates cell cycle, cell survival, apoptosis, and differentiation and cooperates with middle T antigen (MT) to transform primary cells in vitro and in vivo. Like all polyomavirus T antigens, PyST functions largely via its interactions with host cell proteins. Here, we show that PyST binds both Yes-associated protein 1 (YAP1) and YAP2, integral parts of the Hippo signaling pathway, which is a subject of increasing interest in human cancer. The transcription factor TEAD, which is a known target of YAP, is also found in PyST complexes. PyST enhanced YAP association with protein phosphatase 2A (PP2A), leading to decreased YAP phosphorylation. PyST increased YAP levels by decreasing its degradation. This effect was mediated by a reduction in YAP association with beta-transducin repeat protein (beta TRCP), which is known to regulate YAP turnover in a phosphorylation-dependent manner. Genetic analysis has identified PyST mutants defective in YAP binding. These mutants demonstrated that YAP binding is important for PyST to block myoblast differentiation and to synergize with the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) to promote cell death in 3T3-L1 preadipocytes placed under differentiation conditions. In addition to YAP binding, both of these phenotypes require PyST binding to PP2A. IMPORTANCE The Hippo/YAP pathway is a highly conserved cascade important for tissue development and homeostasis. Defects in this pathway are increasingly being associated with cancer. Polyomavirus small t antigen is a viral oncogene that cooperates with middle T antigen in transformation. On its own, small t antigen controls cell survival and differentiation. By binding YAP, small t antigen brings it together with protein phosphatase 2A. This work shows how this association of small t antigen with YAP is important for its effects on cell phenotype. It also suggests that PyST can be used to characterize cellular processes that are regulated by YAP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

Sylvan C. Baca, David Y. Takeda, Ji-Heui Seo, Justin Hwang, Sheng Yu Ku, Rand Arafeh, Taylor Arnoff, Supreet Agarwal, Connor Bell, Edward O'Connor, Xintao Qiu, Sarah Abou Alaiwi, Rosario I. Corona, Marcos A. S. Fonseca, Claudia Giambartolomei, Paloma Cejas, Klothilda Lim, Monica He, Anjali Sheahan, Amin Nassar, Jacob E. Berchuck, Lisha Brown, Holly M. Nguyen, Ilsa M. Coleman, Arja Kaipainen, Navonil De Sarkar, Peter S. Nelson, Colm Morrissey, Keegan Korthauer, Mark M. Pomerantz, Leigh Ellis, Bogdan Pasaniuc, Kate Lawrenson, Kathleen Kelly, Amina Zoubeidi, William C. Hahn, Himisha Beltran, Henry W. Long, Myles Brown, Eva Corey, Matthew L. Freedman

Summary: The study reveals that the transcription factor FOXA1 plays a crucial role in the development of neuroendocrine prostate cancer (NEPC) by regulating specific regulatory elements. Additionally, the expression of NE lineage TFs ASCL1 and NKX2-1 in PRAD cells can reprogram FOXA1 to bind to NE regulatory elements and induce enhancer activity.

NATURE COMMUNICATIONS (2021)

Article Oncology

Prostate Cancer Mortality Associated with Aggregate Polymorphisms in Androgen-Regulating Genes: The Atherosclerosis Risk in the Communities (ARIC) Study

Anna E. Prizment, Sean McSweeney, Nathan Pankratz, Corinne E. Joshu, Justin H. Hwang, Elizabeth A. Platz, Charles J. Ryan

Summary: The alterations in androgen-regulating genes can impact the prognosis of prostate cancer, with HSD3B1 gene variation associated with increased risk of prostate cancer death in men with metastatic disease. There is a cumulative effect of these genes on prostate cancer-specific mortality, with further validation needed.

CANCERS (2021)

Article Cell Biology

SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization

Chao Dai, Jonathan P. Rennhack, Taylor E. Arnoff, Maneesha Thaker, Scott T. Younger, John G. Doench, August Yue Huang, Annan Yang, Andrew J. Aguirre, Belinda Wang, Evan Mun, Joyce T. O'Connell, Ying Huang, Katherine Labella, Jessica A. Talamas, Ji Li, Nina Ilic, Justin Hwang, Andrew L. Hong, Andrew O. Giacomelli, Ole Gjoerup, David E. Root, William C. Hahn

Summary: Metastasis is a complex and poorly understood process, especially in pancreatic cancer where loss of SMAD4 is correlated with metastatic disease and poor prognosis. This study identified FOSL1 as a SMAD4 target that plays a critical role in driving colonization to the lung, suggesting that early targeting of these genes may provide therapeutic benefits.

CELL REPORTS (2021)

Article Cell Biology

YAP1 and PRDM14 converge to promote cell survival and tumorigenesis

Miju Kim, Seav Huong Ly, Yingtian Xie, Gina N. Duronio, Dane Ford-Roshon, Justin H. Hwang, Rita Sulahian, Jonathan P. Rennhack, Jonathan So, Ole Gjoerup, Jessica A. Talamas, Maximilien Grandclaudon, Henry W. Long, John G. Doench, Nilay S. Sethi, Marios Giannakis, William C. Hahn

Summary: Transcriptional co-activator YAP1 is crucial for cell proliferation, survival, and tumorigenesis. This study reveals that the transcription factor PRDM14 can rescue YAP1-dependent colon cancer cells by upregulating the expression of CALM2 and SLC2A1.

DEVELOPMENTAL CELL (2022)

Article Multidisciplinary Sciences

Biologically informed deep neural network for prostate cancer discovery

Haitham A. Elmarakeby, Justin Hwang, Rand Arafeh, Jett Crowdis, Sydney Gang, David Liu, Saud H. AlDubayan, Keyan Salari, Steven Kregel, Camden Richter, Taylor E. Arnoff, Jihye Park, William C. Hahn, Eliezer M. Van Allen

Summary: The development of a biologically informed deep learning model P-NET enables stratification of prostate cancer patients by treatment-resistance state and evaluation of molecular drivers of treatment resistance for therapeutic targeting with complete model interpretability. This approach shows superior performance in cancer state prediction using molecular data compared to other modeling approaches.

NATURE (2021)

Article Cell Biology

A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer

Stephen Tang, Vidyalakshmi Sethunath, Nebiyou Y. Metaferia, Marina F. Nogueira, Daniel S. Gallant, Emma R. Garner, Lauren A. Lairson, Christopher M. Penney, Jiao Li, Maya K. Gelbard, Sarah Abou Alaiwi, Ji-Heui Seo, Justin H. Hwang, Craig A. Strathdee, Sylvan C. Baca, Shatha AbuHammad, Xiaoyang Zhang, John G. Doench, William C. Hahn, David Y. Takeda, Matthew L. Freedman, Peter S. Choi, Srinivas R. Viswanathan

Summary: AR signaling in prostate cancer is driven by protein arginine methyltransferase 1 (PRMT1), which regulates AR recruitment and expression. Inhibition of PRMT1 impairs AR binding at specific sites and decreases expression of key oncogenes. Combined inhibition of AR and PRMT1 shows unique sensitivity in AR-driven prostate cancer cells.

CELL REPORTS (2022)

Article Biology

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies

Justin H. Hwang, Rand Arafeh, Ji-Heui Seo, Sylvan C. Baca, Megan Ludwig, Taylor E. Arnoff, Lydia Sawyer, Camden Richter, Sydney Tape, Hannah E. Bergom, Sean McSweeney, Jonathan P. Rennhack, Sarah A. Klingenberg, Alexander T. M. Cheung, Jason Kwon, Jonathan So, Steven Kregel, Eliezer M. Van Allen, Justin M. Drake, Matthew L. Freedman, William C. Hahn

Summary: The study reveals the physical interactions between CREB5, AR, and FOXA1 in mCRPC, and their association with critical nuclear factors and pathways that promote ART resistance.

ELIFE (2022)

Article Oncology

Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer

Xiaolei Shi, Abderrahman Day, Hannah E. Bergom, Sydney Tape, Sylvan C. Baca, Zoi E. Sychev, Gabrianne Larson, Asha Bozicevich, Justin M. Drake, Nicholas Zorko, Jinhua Wang, Charles J. Ryan, Emmanuel S. Antonarakis, Justin Hwang

Summary: The study identifies B7-H3 as an immune checkpoint overexpressed in prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide-resistant mCRPC cells show increased expression of B7-H3, and it is associated with resistance signaling pathways. The gene network of B7-H3 is strongly correlated with androgen receptor (AR) and its co-factors, suggesting potential therapeutic targets for mCRPC.

NPJ PRECISION ONCOLOGY (2022)

Article Endocrinology & Metabolism

ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer

Song Yi Bae, Hannah E. Bergom, Abderrahman Day, Joseph T. Greene, Zoi E. Sychev, Gabrianne Larson, Eva Corey, Stephen R. Plymate, Tanya S. Freedman, Justin H. Hwang, Justin M. Drake

Summary: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype characterized by loss of androgen receptor signaling and transdifferentiation toward small-cell neuroendocrine phenotypes. Using SCN phenotype scores and gene depletion screens, ZBTB7A was identified as a candidate promoting NEPC progression. High SCN phenotype scores correlated with reliance on RET kinase activity and dependence on ZBTB7A. ZBTB7A showed distinct gene networking patterns in NEPC compared to prostate adenocarcinoma, with a strong association with genes promoting cell cycle progression. Silencing ZBTB7A suppressed cell growth and induced apoptosis in NEPC cell lines.

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Biology

ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems

Hannah E. Bergom, Ashraf Shabaneh, Abderrahman Day, Atef Ali, Ella Boytim, Sydney Tape, John R. Lozada, Xiaolei Shi, Carlos Perez Kerkvliet, Sean McSweeney, Samuel P. Pitzen, Megan Ludwig, Emmanuel S. Antonarakis, Justin M. Drake, Scott M. Dehm, Charles J. Ryan, Jinhua Wang, Justin Hwang

Summary: ALAN is an informatics approach that develops gene signatures, identifies gene targets, and interprets mechanisms of cancer progression or therapy resistance. It compares gene behavior based on patient -omic data, identifying various types of gene behaviors. ALAN discovered direct protein-protein interactions in prostate cancer and complex networks associated with the proto-oncogene MYC in different cancer types and within cancer subtypes.

COMMUNICATIONS BIOLOGY (2023)

Article Oncology

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

Alex Chehrazi-Raffle, Hanna Tukachinsky, Eamon Toye, Smruthy Sivakumar, Alexa B. Schrock, Hannah E. Bergom, Hedyeh Ebrahimi, Sumanta Pal, Tanya Dorff, Neeraj Agarwal, Brandon A. Mahal, Geoffrey R. Oxnard, Justin Hwang, Emmanuel S. Antonarakis

Summary: In this study, the nature of BRAF alterations in prostate cancer was characterized using comprehensive genomic profiling of tissue and liquid biopsies. The results showed that activating BRAF alterations were detected in approximately 3% of prostate cancers, with the majority being class II mutations and rearrangements. These BRAF-altered prostate cancers were enriched for CDK12 mutations but depleted in TMPRSS2 fusions, PTEN alterations, and APC alterations. Furthermore, BRAF alterations were more common in tumors from patients of African and Asian ancestry compared to patients of European ancestry.

CLINICAL CANCER RESEARCH (2023)

Article Cell Biology

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma

Frank Cichocki, Bin Bin Zhang, Cheng-Ying Wu, Emily Chiu, Abderrahman Day, Roddy S. O'Connor, Dima Yackoubov, Ronit Simantov, David H. McKenna, Qing Cao, Todd E. Defor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Nathaniel Snyder, Akhilesh Kumar, Bartosz Grzywacz, Justin Hwang, Yona Geffen, Jeffrey S. Miller, Joseph Maakaron, Veronika Bachanova

Summary: Allogeneic natural killer (NK) cell adoptive transfer, enhanced by ex vivo culture with interleukin-15 (IL-15) and nicotinamide (NAM), leads to stable induction of l-selectin (CD62L), and metabolic changes associated with elevated glucose flux. This approach improves NK cell survival, function, and persistence, and shows promising results in a clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The therapy, named GDA-201, demonstrates high tolerability, favorable metabolic profile, and an overall response rate of 74% in advanced NHL patients.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Editorial Material Endocrinology & Metabolism

Editorial: Hormone resistance in cancer

John T. Phoenix, Audris Budreika, Raymond J. Kostlan, Justin H. Hwang, Sean W. Fanning, Steven Kregel

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Oncology

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Ralph E. E. White, Maxwell Bannister, Abderrahman Day, Hannah E. E. Bergom, Victor M. M. Tan, Justin Hwang, Hai Dang Nguyen, Justin M. M. Drake

Summary: Prostate cancer (PCa) is the most diagnosed non-skin cancer in American males. Patients with localized prostate cancer are treated with androgen deprivation therapies (ADTs), which inhibit androgen production and the androgen receptor (AR). However, some patients develop resistance to ADTs and progress to castration-resistant prostate cancer (CRPC). In this study, the researchers found that the SRC kinase inhibitor, saracatinib, synergizes with enzalutamide, a second-generation hormonal therapy, in specific types of CRPC cell lines. This combination strategy could potentially improve treatment outcomes for patients expressing both AR-FL and AR-Vs.

FRONTIERS IN ONCOLOGY (2023)

Article Medicine, Research & Experimental

RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics

Raie T. Bekele, Amruta S. Samant, Amin H. Nassar, Jonathan So, Elizabeth P. Garcia, Catherine R. Curran, Justin H. Hwang, David L. Mayhew, Anwesha Nag, Aaron R. Thorner, Judit Borcsok, Zsofia Sztupinszki, Chong-Xian Pan, Joaquim Bellmunt, David J. Kwiatkowski, Guru P. Sonpavde, Eliezer M. Van Allen, Kent W. Mouw

Summary: The study identified RAF1 activation as a dependency in a subset comprising nearly 20% of urothelial tumors, suggesting that targeting RAF1-mediated signaling may represent a rational therapeutic strategy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available